腰仙部神経根痛管理の世界市場レポート2025年

腰仙部神経根痛管理の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.5％で、11億1,000万米ドルに成長します。予測期間中に予想される成長は、低侵襲手術技術の革新、生物学的療法の採用増加、個別化疼痛管理の重視の高まり、外来疼痛クリニックの需要増加、デジタルヘルスと遠隔医療の疼痛管理診療への統合に起因すると考えられます。この期間に予想される主要動向には、低侵襲脊椎手術の進歩、神経刺激装置の発展、血小板豊富血漿などの生物学的療法の使用、AI主導の診断と個別化治療戦略の適用、新しい非オピオイド鎮痛薬の開発などがあります。

腰痛障害の有病率の増加は、今後数年間の腰仙部神経根痛管理市場の成長を促進すると予想されます。腰痛症は、背中の背骨、筋肉、神経に影響を及ぼし、不快感や痛みをもたらすさまざまな症状を包含します。この増加は、背中の筋肉を弱め、姿勢の悪さや慢性的な痛みを引き起こす座りっぱなしのライフスタイルに大きく起因しています。腰仙部神経根痛管理は、腰の神経根の炎症を緩和することで、痛みや炎症を軽減し、可動性を回復させ、生活の質全体を高めることに焦点を当てています。例えば、2024年6月、政府機関であるオーストラリア保健福祉ラボは、2022年、腰の問題による入院の半数以上（52％）が腰痛または脊髄痛によるものであり、腰痛が27％と最も高い割合を占め、次いで頚部痛が6.2％、神経根症が6.0％であったと報告しました。さらに、腰痛は2023年の総健康負担の4.3%を占め、第3位となりました。その結果、背部痛疾患の有病率の増加は、腰仙部神経根痛管理市場の拡大を促進する重要な要因となっています。

腰仙部神経根痛管理市場の主要企業は、長期にわたる疼痛緩和のための非オピオイド選択肢を提供するため、治験中の経口NaV1.8疼痛シグナル阻害剤などの先進治療の開発に注力しています。これらの治験薬はNaV1.8ナトリウムチャネルを標的としており、感覚神経を通じて痛みのシグナルを伝達する上で重要な役割を担っています。例えば、2024年12月、米国のバイオテクノロジー企業であるVertex Pharmaceuticalsは、有痛性腰仙椎神経根症（LSR）に対するスゼトリギンの第2相臨床検査の結果を発表しました。本検査は主要評価項目を達成し、スゼトリギンを投与された患者においてベースラインから統計学的に有意かつ臨床的に意義のある疼痛の軽減が示されました。本剤の忍容性は概して良好で、重篤な有害事象は報告されなかりました。バーテックス社は、本検査で観察された高いプラセボ反応について、今後の第3相検査で対処し、本剤の有効性をより適切に評価する予定です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の腰仙部神経根痛管理：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の腰仙部神経根痛管理市場：成長率分析
• 世界の腰仙部神経根痛管理市場の実績：規模と成長、2019～2024年
• 世界の腰仙部神経根痛管理市場の予測：規模と成長、2024～2029年、2034年
• 世界の腰仙部神経根痛管理：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の腰仙部神経根痛管理市場：薬別、実績と予測、2019～2024年、2024～2029年、2034年
• 非ステロイド性抗炎症薬
• オピオイド
• 抗うつ薬
• 抗けいれん薬
• ステロイド
• 世界の腰仙部神経根痛管理市場：理学療法別、実績と予測、2019～2024年、2024～2029年、2034年
• 手技療法
• 運動療法
• 電気療法
• 温熱療法
• ハイドロセラピー
• 世界の腰仙部神経根痛管理市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 局所
• 世界の腰仙部神経根痛管理市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の腰仙部神経根痛管理市場、非ステロイド性抗炎症薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イブプロフェン
• ナプロキセン
• ジクロフェナク
• セレコキシブ
• エトリコキシブ
• 世界の腰仙部神経根痛管理市場、オピオイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• トラマドール
• オキシコドン
• モルヒネ
• ヒドロコドン
• フェンタニル
• 世界の腰仙部神経根痛管理市場、抗うつ薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アミトリプチリン
• ノルトリプチリン
• デュロキセチン
• デスベンラファキシン
• ベンラファキシン
• 世界の腰仙部神経根痛管理市場、抗てんかん薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ガバペンチン
• プレガバリン
• カルバマゼピン
• ラモトリギン
• トピラマート
• 世界の腰仙部神経根痛管理市場、ステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• デキサメタゾン
• メチルプレドニゾロン
• プレドニゾン
• トリアムシノロン
• ヒドロコルチゾン

第7章 地域別・国別分析

• 世界の腰仙部神経根痛管理市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の腰仙部神経根痛管理市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腰仙部神経根痛管理市場：競合情勢
• 腰仙部神経根痛管理市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Sanofi SA
  • Bristol-Myers Squibb

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GSK plc
• Medtronic plc
• Eli Lilly and Company
• Amgen Inc
• Koninklijke Philips NV
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd
• Boston Scientific Corporation
• Dr Reddy's Laboratories Ltd
• NuVasive Inc.
• Nobel Biocare Holdings AG
• Ultradent Products Inc.
• Nevro Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 腰仙部神経根痛管理市場、2029年：新たな機会を提供する国
• 腰仙部神経根痛管理市場、2029年：新たな機会を提供するセグメント
• 腰仙部神経根痛管理市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Lumbosacral radicular pain management involves a comprehensive strategy for diagnosing, treating, and alleviating pain caused by irritation or compression of the spinal nerve roots in the lumbosacral region (lower back and sacral area). This condition is often linked to issues such as herniated discs, spinal stenosis, or degenerative disc disease. Treatment focuses on reducing inflammation, relieving pressure on the affected nerves, and supporting functional recovery. The primary goal is to improve mobility, reduce pain, and enhance the patient's overall quality of life.

The key categories of medications used in managing lumbosacral radicular pain include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, anticonvulsants, and steroids. NSAIDs are commonly used as a first-line treatment to alleviate pain and inflammation by blocking the enzymes responsible for inflammation. Management may also involve various physical therapies, including manual therapy, exercise therapy, electrotherapy, thermal therapy, and hydrotherapy. These treatments are delivered through different routes, such as oral and topical administration, and are made available through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The lumbosacral radicular pain management market research report is one of a series of new reports from The Business Research Company that provides lumbosacral radicular pain management market statistics, including the lumbosacral radicular pain management industry global market size, regional shares, competitors with the lumbosacral radicular pain management market share, detailed lumbosacral radicular pain management market segments, market trends, opportunities, and any further data you may need to thrive in the lumbosacral radicular pain management industry. This lumbosacral radicular pain management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lumbosacral radicular pain management market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.90 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of lumbar disc herniation, heightened awareness of spinal disorders, a growing elderly population, advancements in diagnostic imaging technologies, and the broader adoption of non-invasive pain management therapies.

The lumbosacral radicular pain management market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period can be attributed to innovations in minimally invasive surgical techniques, the rising adoption of biologic therapies, an increasing emphasis on personalized pain management, growing demand for outpatient pain clinics, and the integration of digital health and telemedicine into pain management practices. Key trends expected during this period include progress in minimally invasive spine surgeries, advancements in neurostimulation devices, the use of biologic therapies such as platelet-rich plasma, the application of AI-driven diagnostics and personalized treatment strategies, and the development of new non-opioid analgesics.

The increasing prevalence of back pain disorders is expected to drive the growth of the lumbosacral radicular pain management market in the coming years. Back pain disorders encompass various conditions affecting the spine, muscles, or nerves in the back, resulting in discomfort or pain. This rise is largely attributed to sedentary lifestyles that weaken back muscles, leading to poor posture and chronic pain. Lumbosacral radicular pain management focuses on alleviating nerve root irritation in the lower back, thereby reducing pain and inflammation, restoring mobility, and enhancing overall quality of life. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that in 2022, more than half (52%) of hospitalizations for back problems were due to back or spinal pain, with lower back pain accounting for the highest proportion at 27%, followed by neck pain at 6.2% and radiculopathy at 6.0%. Additionally, back problems had become the third leading contributor to the total health burden in 2023, representing 4.3% of the overall impact. As a result, the growing prevalence of back pain disorders is a key factor fueling the expansion of the lumbosacral radicular pain management market.

Leading companies in the lumbosacral radicular pain management market are concentrating on developing advanced therapies, such as investigational oral NaV1.8 pain signal inhibitors, to provide non-opioid options for long-lasting pain relief. These investigational drugs target the NaV1.8 sodium channel, a critical component in transmitting pain signals through sensory nerves. For example, in December 2024, Vertex Pharmaceuticals, a U.S.-based biotechnology company, released results from its Phase 2 clinical trial of suzetrigine for treating painful lumbosacral radiculopathy (LSR). The trial achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in pain from baseline in patients receiving suzetrigine. The drug was generally well tolerated, with no serious adverse events reported. Vertex plans to address the high placebo response observed in the study in upcoming Phase 3 trials to better evaluate the drug's efficacy.

In October 2024, Stryker Corporation, a U.S.-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. Through this acquisition, Stryker seeks to expand its interventional pain management portfolio, increase its footprint in ambulatory surgery centers, and enhance its capabilities in minimally invasive treatments for chronic lower back pain. Vertos Medical Inc. is a U.S.-based company specializing in interventional pain management solutions, particularly the minimally invasive mild(R) procedure for treating lumbar spinal stenosis.

Major players in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy's Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

North America was the largest region in the lumbosacral radicular pain management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lumbosacral radicular pain management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lumbosacral radicular pain management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lumbosacral radicular pain management market consists of revenues earned by entities by providing services such as psychological therapy, surgical intervention, chiropractic care, and pharmacological management. The market value includes the value of related goods sold by the service provider or included within the service offering. The lumbosacral radicular pain management market includes sales of muscle relaxants, epidural steroid injections, and nerve blocks. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lumbosacral Radicular Pain Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lumbosacral radicular pain management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lumbosacral radicular pain management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lumbosacral radicular pain management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Medication: Non-Steroidal Anti-Inflammatory Drugs; Opioids; Antidepressants; Anticonvulsants; Steroids
• 2) By Physical Therapy: Manual Therapy; Exercise Therapy; Electrotherapy; Thermal Therapy; Hydrotherapy
• 3) By Route Of Administration: Oral; Topical
• 4) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen; Naproxen; Diclofenac; Celecoxib; Etoricoxib
• 2) By Opioids: Tramadol; Oxycodone; Morphine; Hydrocodone; Fentanyl
• 3) By Antidepressants: Amitriptyline; Nortriptyline; Duloxetine; Desvenlafaxine; Venlafaxine
• 4) By Anticonvulsants: Gabapentin; Pregabalin; Carbamazepine; Lamotrigine; Topiramate
• 5) By Steroids: Dexamethasone; Methylprednisolone; Prednisone; Triamcinolone; Hydrocortison
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Bayer AG; Sanofi SA; Bristol-Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lumbosacral Radicular Pain Management Market Characteristics

3. Lumbosacral Radicular Pain Management Market Trends And Strategies

4. Lumbosacral Radicular Pain Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lumbosacral Radicular Pain Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lumbosacral Radicular Pain Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lumbosacral Radicular Pain Management Market Growth Rate Analysis
• 5.4. Global Lumbosacral Radicular Pain Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lumbosacral Radicular Pain Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lumbosacral Radicular Pain Management Total Addressable Market (TAM)

6. Lumbosacral Radicular Pain Management Market Segmentation

• 6.1. Global Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs
• Opioids
• Antidepressants
• Anticonvulsants
• Steroids
• 6.2. Global Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Manual Therapy
• Exercise Therapy
• Electrotherapy
• Thermal Therapy
• Hydrotherapy
• 6.3. Global Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• 6.4. Global Lumbosacral Radicular Pain Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Lumbosacral Radicular Pain Management Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Diclofenac
• Celecoxib
• Etoricoxib
• 6.6. Global Lumbosacral Radicular Pain Management Market, Sub-Segmentation Of Opioids, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tramadol
• Oxycodone
• Morphine
• Hydrocodone
• Fentanyl
• 6.7. Global Lumbosacral Radicular Pain Management Market, Sub-Segmentation Of Antidepressants, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amitriptyline
• Nortriptyline
• Duloxetine
• Desvenlafaxine
• Venlafaxine
• 6.8. Global Lumbosacral Radicular Pain Management Market, Sub-Segmentation Of Anticonvulsants, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gabapentin
• Pregabalin
• Carbamazepine
• Lamotrigine
• Topiramate
• 6.9. Global Lumbosacral Radicular Pain Management Market, Sub-Segmentation Of Steroids, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Methylprednisolone
• Prednisone
• Triamcinolone
• Hydrocortisone

7. Lumbosacral Radicular Pain Management Market Regional And Country Analysis

• 7.1. Global Lumbosacral Radicular Pain Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lumbosacral Radicular Pain Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lumbosacral Radicular Pain Management Market

• 8.1. Asia-Pacific Lumbosacral Radicular Pain Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lumbosacral Radicular Pain Management Market

• 9.1. China Lumbosacral Radicular Pain Management Market Overview
• 9.2. China Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lumbosacral Radicular Pain Management Market

• 10.1. India Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lumbosacral Radicular Pain Management Market

• 11.1. Japan Lumbosacral Radicular Pain Management Market Overview
• 11.2. Japan Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lumbosacral Radicular Pain Management Market

• 12.1. Australia Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lumbosacral Radicular Pain Management Market

• 13.1. Indonesia Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lumbosacral Radicular Pain Management Market

• 14.1. South Korea Lumbosacral Radicular Pain Management Market Overview
• 14.2. South Korea Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lumbosacral Radicular Pain Management Market

• 15.1. Western Europe Lumbosacral Radicular Pain Management Market Overview
• 15.2. Western Europe Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lumbosacral Radicular Pain Management Market

• 16.1. UK Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lumbosacral Radicular Pain Management Market

• 17.1. Germany Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lumbosacral Radicular Pain Management Market

• 18.1. France Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lumbosacral Radicular Pain Management Market

• 19.1. Italy Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lumbosacral Radicular Pain Management Market

• 20.1. Spain Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lumbosacral Radicular Pain Management Market

• 21.1. Eastern Europe Lumbosacral Radicular Pain Management Market Overview
• 21.2. Eastern Europe Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lumbosacral Radicular Pain Management Market

• 22.1. Russia Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lumbosacral Radicular Pain Management Market

• 23.1. North America Lumbosacral Radicular Pain Management Market Overview
• 23.2. North America Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lumbosacral Radicular Pain Management Market

• 24.1. USA Lumbosacral Radicular Pain Management Market Overview
• 24.2. USA Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lumbosacral Radicular Pain Management Market

• 25.1. Canada Lumbosacral Radicular Pain Management Market Overview
• 25.2. Canada Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lumbosacral Radicular Pain Management Market

• 26.1. South America Lumbosacral Radicular Pain Management Market Overview
• 26.2. South America Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lumbosacral Radicular Pain Management Market

• 27.1. Brazil Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lumbosacral Radicular Pain Management Market

• 28.1. Middle East Lumbosacral Radicular Pain Management Market Overview
• 28.2. Middle East Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lumbosacral Radicular Pain Management Market

• 29.1. Africa Lumbosacral Radicular Pain Management Market Overview
• 29.2. Africa Lumbosacral Radicular Pain Management Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lumbosacral Radicular Pain Management Market, Segmentation By Physical Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lumbosacral Radicular Pain Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lumbosacral Radicular Pain Management Market Competitive Landscape And Company Profiles

• 30.1. Lumbosacral Radicular Pain Management Market Competitive Landscape
• 30.2. Lumbosacral Radicular Pain Management Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Lumbosacral Radicular Pain Management Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Medtronic plc
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc
• 31.7. Koninklijke Philips NV
• 31.8. Stryker Corporation
• 31.9. Teva Pharmaceutical Industries Ltd
• 31.10. Boston Scientific Corporation
• 31.11. Dr Reddy's Laboratories Ltd
• 31.12. NuVasive Inc.
• 31.13. Nobel Biocare Holdings AG
• 31.14. Ultradent Products Inc.
• 31.15. Nevro Corp.

32. Global Lumbosacral Radicular Pain Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lumbosacral Radicular Pain Management Market

34. Recent Developments In The Lumbosacral Radicular Pain Management Market

35. Lumbosacral Radicular Pain Management Market High Potential Countries, Segments and Strategies

• 35.1 Lumbosacral Radicular Pain Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lumbosacral Radicular Pain Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lumbosacral Radicular Pain Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer